Exploratory Clinical Trial Grants in Arthritis and Musculoskeletal and Skin Diseases (R61 Clinical Trial Required)
Funding available for exploratory clinical trials in arthritis, musculoskeletal, and skin diseases; updated application review process.
Funder: National Institutes of Health
Due Dates: July 2, 2025 (New/Renewal/Resubmission/Revision) | Nov 4, 2025 (New/Renewal/Resubmission/Revision) | Mar 4, 2026 (New/Renewal/Resubmission/Revision) | July 2, 2026 (New/Renewal/Resubmission/Revision) | Nov 2, 2026 (New/Renewal/Resubmission/Revision)
Funding Amounts: Up to $600,000 direct costs over 3 years; no more than $300,000 direct costs in any single year.
Summary: Supports short-term exploratory clinical trials in arthritis, musculoskeletal, and skin diseases to advance prevention, diagnosis, or treatment.
Key Information: Clinical trial is required; updated review criteria apply for due dates on or after Jan 25, 2025.
Description
This opportunity supports exploratory (R61) clinical trials focused on arthritis, musculoskeletal, and skin diseases. The program is designed to facilitate short-term, interventional studies that can be completed within a limited timeframe and budget. Projects should address research questions aligned with the mission and goals of the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), and may evaluate interventions involving drugs, biologics, devices, surgical, dietary, behavioral, or rehabilitation therapies.
The program aims to stimulate the translation of promising research from laboratory, preclinical, or early human testing into clinical practice. Studies may range from proof-of-concept and first-in-human to early phase I/II trials. Large-scale efficacy or effectiveness trials are not supported under this mechanism.
